Background: High-sensitivity C-reactive protein (hs-CRP) is an inflammatory marker that has been suggested as a predictor of cardiovascular diseases. High glycated hemoglobin (HbA1c) levels and overweight/obesity are independently associated with elevated hs-CRP; meanwhile, high HbA1c levels are frequently accompanied by overweight or obesity. However, their joint effect on elevated hs-CRP levels has not been well-established. Therefore, we evaluated whether overweight/obesity modified the association between high HbA1c levels and elevated hs-CRP.

Methods: Based on cross-sectional data from the Chinese Urban Adults Diet and Health Study (CUADHS) in 2016, we included 1,630 adults aged 18-75 years (mean age 50.16 years and 33.6% male). Elevated hs-CRP was defined as serum hs-CRP ≥ 3 and <10 mg/L. The interactive effects of BMI and HbA1c levels on the risk of elevated hs-CRP levels were calculated by using multiple logistic regression models, followed by strata-specific analyses.

Results: Individuals with elevated hs-CRP had a higher rate of HbA1c level than those without elevated (25.3 vs. 11.3%, < 0.001), as well as a higher rate of overweight/obesity (67.1 vs. 43.5%, < 0.001). Higher HbA1c levels were independently associated with an increased risk of elevated hs-CRP [adjusted odds ratio (aOR) = 2.31, 95% confidence interval (CI): 1.47, 3.65], as well as overweight/obesity with the risk of elevated hs-CRP (aOR = .31, 95% confidenc-3.73). Furthermore, overweight/obesity showed a significant synergistic effect on high HbA1c levels with a higher aOR of 5.25 (2.77, 9.95) ( < 0.001). This synergistic effect was more prominent when stratified by age (in 18-44 years old, aOR, 95% CI = 30.90, 4.40-236.47 for interaction vs. 6.46, 1.38-30.23 for high HbA1c only) and gender (in women, aOR, 95% CI = 8.33, 3.80-18.23 for interaction vs. 2.46,1.38-4.40 for high HbA1c only).

Conclusion: There are synergistic effects of high HbA1c levels and overweight/obesity on the risk of elevated hs-CRP in Chinese adults, with more significant effects in adults aged 18-44 years or females. Intervention strategies for preventing high blood glucose levels and body weight simultaneously may be important for reducing hs-CRP-related diseases. Further studies are needed to confirm this finding in other populations, and its molecular mechanisms need to be elucidated.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196946PMC
http://dx.doi.org/10.3389/fnut.2023.1156404DOI Listing

Publication Analysis

Top Keywords

hba1c levels
12
elevated hs-crp
12
high-sensitivity c-reactive
8
c-reactive protein
8
high hba1c
8
elevated
5
hs-crp
5
synergistic effects
4
effects overweight/obesity
4
high
4

Similar Publications

Sarcopenia in independent oldest-old individuals treated for diabetes, with or without metformin: a case-control study.

Acta Diabetol

January 2025

Discipline of Geriatrics and Gerontology, Paulista School of Medicine, Federal University of São Paulo, Rua dos Otonis, 863, Vila Clementino, São Paulo, SP, ZIP CODE 04025-002, Brazil.

Background: Sarcopenia is a common condition in the elderly, especially in diabetics (DM). Metformin (MTF), known to reduce glucose levels, can also be a therapeutic intervention in age-related diseases, although it may contribute to muscle loss.

Objectives: To compare the prevalence of sarcopenia among elderly people treated for DM, with or without MTF, and non-diabetic patients (NDM) and evaluate whether there is an association between the use of MTF and the development of sarcopenia.

View Article and Find Full Text PDF

Objective: To evaluate the impact of a 4-month dietary and lifestyle program co-designed and led by Aboriginal and Torres Strait Islander people on weight and metabolic markers, diet, and physical activity in overweight and obese adults in a remote Indigenous community.

Study Design: Single arm, pre-post intervention study.

Setting, Participants: Adult residents (18-65 years) of a remote Northern Territory community with body mass index (BMI) values of at least 25 kg/m or waist circumferences exceeding 94 cm (men) or 80 cm (women).

View Article and Find Full Text PDF

Aims: To compare the risk of all-cause death and cardiovascular events in new users of insulin glargine, glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), particularly in subgroups defined by baseline haemoglobin A1C (HbA1C), body mass index (BMI) and estimated glomerular filtration rate (eGFR).

Materials And Methods: We conducted an active comparator, new user design study in a national cohort of 161 405 veterans with type 2 diabetes (T2D) on metformin and initiated insulin glargine (n = 54 375), GLP-1RA (n = 22 145) or SGLT2i (n = 84 885) between 1 January 2018 and 31 December 2021. Patients were followed until 31 March 2023.

View Article and Find Full Text PDF

A Mobile Health Intervention for Improving Problem-Solving Skills, Emotional Adaptation, and Glycemic Control in Patients With Type 2 Diabetes.

Res Nurs Health

January 2025

Department of Internal Medicine and Center for Tissue Engineering, Division of Endocrinology and Metabolism, Chang Gung Memorial Hospital, Taoyuan, Taiwan ROC.

Mobile health (mHealth) enables health-care professionals to assist patients with type 2 diabetes (T2D) in effective self-management of the disease. Using a quasi-experimental design, we evaluated the effectiveness of a nurse-led mHealth problem-solving program (mHealth-PSP) in enhancing problem-solving skills, improving emotional adaptation, and reducing glycated hemoglobin (HbA1c) levels in patients with T2D. The present study included 83 patients with T2D from two hospitals in northern Taiwan.

View Article and Find Full Text PDF

Objectives: This analysis quantifies the potential long-term clinical and cost benefits of early and intensive metabolic control (EIMC) versus conventional management in patients newly diagnosed with type 2 diabetes in Italy.

Methods: The PRIME T2D Model was used to project clinical and cost outcomes over long-term time horizons for a newly diagnosed cohort of patients receiving EIMC or conventional management. EIMC was associated with a mean glycated hemoglobin reduction of 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!